4.5 Review

Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder

Journal

JAMA NEUROLOGY
Volume 72, Issue 7, Pages 815-822

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jamaneurol.2015.0248

Keywords

-

Funding

  1. Bayer Schering Pharma
  2. Biogen Idec
  3. Genzyme
  4. Kael-GemVax
  5. Merck Serono
  6. Novartis
  7. Teva-Handok
  8. UCB
  9. German Research Council
  10. German Ministry of Education and Research (Competence Network Multiple Sclerosis [KKNMS])
  11. GJCF
  12. Bayer
  13. Teva
  14. Merck
  15. Sanofi
  16. Chugai Pharma
  17. Bayer Schering
  18. National MS Society
  19. Roche
  20. Bayer Healthcare
  21. Genzyme Corp
  22. Teva Neuroscience
  23. Ministry of Education, Culture, Sports, Science and Technology in Japan
  24. Ichiro Kanehara Foundation
  25. German Ministry of Science (BMBF/KKNMS)
  26. Canadian MS Research Foundation
  27. Canadian MS Society
  28. Canadian Institutes of Health Research
  29. Multiple Sclerosis Association of America
  30. DioGenix
  31. Amplimmune
  32. Biogen
  33. National Institutes of Health
  34. Patient-Centered Outcomes Research Institute
  35. Acorda Therapeutics
  36. Viropharma
  37. Acorda
  38. NeuralStem
  39. Genentech
  40. European Commission
  41. Instituto Salud Carlos III
  42. Marato TV3
  43. Eisai
  44. Mitsubishi Tanabe Pharma Corp
  45. Novartis Pharma
  46. Astellas Pharma
  47. Takeda Pharmaceutical Company Limited
  48. Asahi Kasei Medical
  49. Daiichi Sankyo
  50. Nihon Pharmaceutical
  51. Biogen Idec Japan
  52. Chemo-Sero-Therapeutic Research Institute
  53. Teva Pharmaceutical
  54. Mitsubishi Tanabe Pharma
  55. Teijin Pharma
  56. Chugai Pharmaceutical
  57. Ono Pharmaceutical
  58. Genzyme Japan
  59. Ministry of Education, Science and Technology in Japan [22229008]
  60. Ministry of Health, Welfare and Labour of Japan
  61. Teva Pharmaceuticals
  62. Opexa Therapeutics
  63. US Department of Veterans Affairs
  64. German Research Council (DFG)
  65. German Ministry of Education and Research (BMBF-EDEN)
  66. Alexion
  67. Terumo BCT

Ask authors/readers for more resources

Brain parenchymal lesions are frequently observed on conventional magnetic resonance imaging (MRI) scans of patients with neuromyelitis optica (NMO) spectrum disorder but the specific morphological and temporal patterns distinguishing them uneqtaivcally from lesions caused by other disorders have not been identified. This literature review summarizes the literature on advanced quantitative imaging measures reported for patients with NMO spectrum disorder, including proton MR spectroscopy, diffusion tensor imaging, magnetization transfer imaging, quantitative MR voltametry, and ultrahigh-field strength MRI. It was undertaken to consider the advanced MRI techniques used for patients with NMO different specialists in the field. Although quantitative measures such as proton MR spectroscopy or magnetization transfer imaging have not reproducibly revealed diffuse brain injury, preliminary data from diffusion-weighted imaging and brain tissue volumetry indicate greater white matter than gray matter degradation. These findings could be confirmed by ultrahigh-field MRI. The use of nonconventional MR I techniques may further our understanding of the pathogenic processes hi NMO spectrum disorders and may help us identify the distinct radiographic features corresponding to specific phenotypic manifestations of this disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available